MMIT helps pharma companies harness the power of real world data to better understand the patient journey.
We’re looking forward to sharing how our solutions can help overcome top business challenges.
Learn more about why it is critical for manufacturers to understand these vendors and patient access implications, in order to formulate a response strategy to ensure appropriate therapy coverage and optimal patient access.
Our Zitter Insights Panel uses research to illuminate the complexities of market access.
October 17, 2023 | 2:00pm EDT
How can your pharma company leverage RWD to strengthen your market access strategy? Watch the webinar to learn how.
Industry Leading Insights
MMIT offers a range of publications for pharma, payers and providers covering news, strategy and insights across the spectrum. Our in-house journalism division AIS Health provides objective news and analysis of industry trends while RJ Health provides a comprehensive look at industry updates as they apply to medically covered drug reimbursement processes.
Over the past two decades, skyrocketing list prices for insulin have threatened medication adherence for the estimated 7.4 million American diabetics who rely on insulin to manage their disease.
For manufacturers, building a static commercialization strategy will only take you so far.
Manufacturers and payers have a role to play in educating patients and providers about the importance of immunizations to combat RSV.
Many pharma companies are surprised to realize that payer coverage is more limited than anticipated, especially in highly competitive markets.
Ever since the Inflation Reduction Act (IRA) became law, pharma companies have struggled to identify how these changes will affect their business.
Since the passing of the Inflation Reduction Act (IRA) last fall, pharma companies have been bracing for the impact of its provisions.
Get the latest from MMIT’s leading subject matter experts, receiving the latest posts right to your inbox. Top-quality thought leadership 100% free.
September 15, 2023
Insulin price caps and list price reductions are a huge step forward for patient access. But what will these changes mean for health plans?
September 13, 2023
Rebate leakage drains millions in revenue from pharma companies every year. To ensure contract compliance, manufacturers can implement these five steps.
September 13, 2023
Buy-and-bill remains the most common distribution channel for provider-administered oncology drugs, but pharmacy channels are still significant, especially for hospital outpatient departments.
September 12, 2023
Infusing a commercialization strategy with real-world data provides a more holistic view of the patient journey.
July 1, 2023
Preliminary data indicate that 2023 may prove to be the most volatile year for health plan enrollment in a decade.
May 31, 2023
The shot’s clearance comes several weeks after the regulator made GSK’s Arexvy the first vaccine for RSV in the U.S.
May 15, 2023
Over the past few decades, pharma companies have perfected the art of using market access data to support product launches, negotiate payer discounts, and secure preferred status and positioning.
May 5, 2023
The Senate Health, Education, Labor and Pensions (HELP) Committee went to work this week to find a bipartisan consensus on measures to reduce prescription drug costs.
May 5, 2023
Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.
May 4, 2023
Four leading specialty pharmacies honored for their dedication to the highest quality customer service.
April 11, 2023
Twelve specialty pharmacies recognized for their dedication to top-quality customer service.
April 7, 2023
In recent years, the rising cost of specialty pharmaceuticals has motivated payers to implement tighter restrictions and seek both traditional and value-based contracts with manufacturers.
March 30, 2023
Payers and physicians recognize manufacturers across seven therapeutic areas who are dedicated to smoothing patient access.
March 13, 2023
By the end of 2023, more than half of the total Medicare population is expected to be enrolled in Medicare Advantage (MA), which has climbed from 25.2 million members in 2020 to 31.5 million members today.
February 22, 2023
Our latest update finds that for 2022, about 40% of commercial lives have adopted these benefit designs.
February 3, 2023
Humira, the best-selling drug used to treat multiple forms of arthritis and other conditions such as ulcerative colitis and Crohn’s disease, finally has some competition.
January 27, 2023
Given the growth of specialty pharmaceuticals, manufacturers will need to develop more aggressive contracting strategies to secure optimal market access for their medical benefit drugs.